R3 International Offering New Stem Cell Therapy for Neuropathy Program in Mexico – Yahoo Finance

R3 International is now offering a new stem cell therapy for neuropathy program in Mexico. The regenerative treatments involve up to 200 million stem cells and have been very effective at relieving neuropathic pain.

SCOTTSDALE, Ariz., July 23, 2020 /PRNewswire-PRWeb/ -- R3 International is now offering a new stem cell therapy for neuropathy program in Mexico. The regenerative treatments involve up to 200 million stem cells and have been very effective at relieving neuropathic pain.

Peripheral neuropathy affects many millions of Individuals worldwide, and often leads to chronic, debilitating pain. It may occur as a result of diabetes, alcoholism, radiation, chemo or many other potential causes.

Stem cell and exosome therapy for neuropathy has achieved tremendous results at R3 International. Stem cells and exosomes are excellent at promoting nerve regeneration and new blood vessel formation.

According to R3 CEO David Greene, MD, MBA, "Patients lament the traditional pain medications they are offered for relief, which may lead to addiction or an overdose. The stem cell and exosome therapy offered at R3 International is safe and very effective for relief and helping patients be able to walk farther."

Treatments at the clinic are outpatient, and involve anywhere from 30 million stem cells up to 200 million. The treatment starts at only $2975, with escorted transportation included from San Diego to the clinic and back. The patient concierge representative goes with the patient to the treatment as well.

The process starts with a free phone consultation with the R3 licensed, experienced stem cell doctor. Once treatment is scheduled, the R3 patient concierge assists with travel logistics.

In addition to the neuropathy stem cell program, R3 International also provides stem cell treatment in Mexico for COPD, kidney failure, autism, arthritis, diabetes, hepatitis, Lyme disease, MS, ALS, Alzheimers and more.

Call (888) 988-0515 to schedule the free phone consultation.

SOURCE R3 Stem Cell International

See original here:
R3 International Offering New Stem Cell Therapy for Neuropathy Program in Mexico - Yahoo Finance

R3 International Now Including Exosomes with Stem Cell Therapy Program for Autism in Mexico – Yahoo Finance

R3 International is now including exosomes with its stem cell therapy program in Mexico for autism. They have been shown to be an effective, safe option for autism patients.

SCOTTSDALE, Ariz., July 23, 2020 /PRNewswire-PRWeb/ --R3 International is now including exosomes with its stem cell therapy program in Mexico for autism. They have been shown to be an effective, safe option for autism patients.

Stem cell and exosome therapy for autism has shown excellent outcomes at R3 International in Tijuana, with the procedures performed by licensed, expert doctors. The doses of biologic are calculated based on the patient's weight. Up to 200 million stem cells are included, along with over 100 billion exosomes.

Autism treatment with regenerative biologics has been very safe and each patient (and family) receives an escort from San Diego to the treatment clinic in Mexico. The autism stem cell treatment center is only twenty minutes from the San Diego International Airport.

According to R3 CEO David Greene, MD, MBA, "Our autism program includes first rate biologics with cell counts that are very high. Safety is paramount, and the lab's safety standards exceed those of the FDA. We set the program up to be extremely cost effective with several options to make it convenient for patient families!"

There are multiple treatment options for autism patients including: 1. A one time visit with 30 or 50 million stem cells starting at $2975. 2. A 5 day stay with several treatments starting at $8975. 3. Several visits over a year period, all inclusive starting at $10,475.

The exosome part of the therapy includes billions of exosomes and is provided at no additional charge. Exosomes are derived from mesenchymal stem cells, and are amazing at cell to cell communication. Research has shown that exosomes are vital in the development of neural circuits, which can enhance the clinical outcomes for autism (Natl Acad Sci, 2019).

To get started with stem cell and exosome therapy for autism in Mexico, call R3 today at (888) 988-0515.

SOURCE R3 Stem Cell International

Visit link:
R3 International Now Including Exosomes with Stem Cell Therapy Program for Autism in Mexico - Yahoo Finance

Selinexor Shows Meaningful, Durable Responses Linked With Improved OS in DLBCL – OncLive

Single-agent selinexor (Xpovio) was found to induce durable responses with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma who had received at least 2 prior lines of chemoimmunotherapy, according to findings from the phase 2b SADAL trial.1

Results showed an overall response rate (ORR) of 28% (n = 36/127; 95% CI, 20.7-37.0), which was the primary end point of the trial; this included a 12% complete response (CR) rate (n = 15) and a 17% partial response (PR) rate (n = 21; 95% CI, 10.5-24.2). The disease control rate (DCR) reported with the agent was 37% (95% CI, 28.6-46.0). Additionally, the median duration of response (DOR) was 9.3 months at a median follow-up of 11.1 months. For those with a CR, the median DOR was even higher, at 23.0 months; it was 4.4 months in those with a PR.

Moreover, at a median follow-up of 14.7 months, the median progression-free survival (PFS) reported with single-agent selinexor was 2.6 months; the median overall survival (OS) was 9.1 months. Median OS was not yet reached in patients who responded to the agent, and it was 18.3 months in those who achieved stable disease. Patients who experienced disease progression or unevaluable response experienced a median OS of 4.3 months. Notably, more than half of the patients, or 65%, who had a target lesion at baseline and at least 1 following baseline assessment experienced a reduction in tumor burden with the treatment.

The clinical outcomes for patients with heavily pretreated relapsed or refractory DLBCL are typically very poor, and hence results from the multinational phase 2b SADAL study are noteworthy, lead author Prof Nagesh Kalakonda, MBBS, MRCP, FRCPath, PhD, of the University of Liverpool, said in a recent press release.2 In this population, single-agent oral selinexor demonstrated an ORR of 28%, including a CR of 12%. Responses were seen in all subgroups, regardless of age, gender, prior therapy, DLBCL subtype or prior stem cell transplant therapyResponses were associated with longer survival, underscoring the potential of oral XPO1 inhibition as an oral, non-chemotherapeutic option for patients with R/R DLBCL.

Patients with DLBCL who relapse following salvage treatment regimens are known to have a notably poor prognosis, which leaves a need for improved treatment options. Selinexor, a selective inhibitor of XPO1, which mediates the functional inactivation tumor suppressor proteins, can activate the growth-regulating effects of these proteins and reverse resistance to chemotherapy. Previously, selinexor monotherapy induced a promising ORR of 32%, with a CR of 10% in a phase 1 study.3,4

The open-label, multicenter, phase 2b SADAL trial, which was conducted in 59 sites spanning 19 countries, was initially designed to evaluate the safety and efficacy of twice weekly selinexor at both a 60-mg dose and a 100-mg dose. Investigators observed that a 60-mg dose yielded an improved therapeutic window in a prespecified interim analysis, this resulting in the discontinuation of the 100-mg cohort.

Patients aged 18 years and older with pathologically confirmed de novo DLBCL or DLBCL that transformed from previously diagnosed indolent lymphoma were permitted to enroll on the trial. Patients also needed to have an ECOG performance score of 0-2 and have experienced progression following 2-5 lines of prior therapy or not be ineligible for autologous stem-cell transplant to participate. Those with primary mediastinal B-cell lymphoma were not included.

Patients who experienced PR or CR during a recent systemic anti-DLBCL therapy needed to wait 60 days before starting selinexor; all others began treatment 14 weeks after their last systemic anti-DLBCL therapy. Patients were given 60 mg of selinexor on day 1 and day 3 of each week until progressive disease, intolerable toxicities, or death. Patients were evaluated via PET and CT scans every 8 weeks to determine DLBCL status.

The primary end point of the trial was OR, and secondary end points included DOR and DCR. Exploratory end points included PFS, OS, time to progression, pharmacokinetic and pharmacodynamic end points, and subgroup analyses.

A total of 267 patients were randomized to either the 60-mg selinexor arm (n = 175) or the 100-mg selinexor arm (n = 92). During the course of the study, 48 patients were excluded, resulting in 127 patients included in the modified intention-to-treat and safety populations. The study saw a high rate of treatment discontinuation in patients who were given selinexor; 93% discontinued because of disease progression, 9 patients died, 7 were discontinued per physician decision, 9 stopped treatment due to adverse effects, and 13 withdrew of their own volition.

Additional results from subgroup analyses revealed a ORR of 34% in patients with germinal center B-cell subtype; this included a 14% CR rate and a 20% PR rate. Seven percent of patients were still responding to treatment at the last disease assessment prior to the data cutoff.

Additionally, the predictive or prognostic biomarker analysis showed that patients who had high c-Myc levels experienced a ORR of 13% and those with low levels had an ORR of 42% (P = .0024). Moreover, patients with a double- or triple-negative expressor status had an ORR of 9.7% versus 40.3% in those without either expressor status (P = .0056). These differences were largely a reflection of c-Myc overexpression because expression levels of neither Bcl-2 nor Bcl-6 affected the ORR, the authors wrote.

With regard to safety, nearly all patients (98%) experienced at least 1 treatment-emergent adverse effect (TEAE). The most common TEAEs reported with the agent included thrombocytopenia (61%), nausea (58%), fatigue (47%), anemia (43%), and decreased appetite (37%), among others. Most TEAEs were grade 1 or 2 in severity. The most common grade 3/4 toxicities included thrombocytopenia (46%), neutropenia (24%), anemia (22%), fatigue (11%), hyponatremia (8%), and nausea (6%). Most of the toxicities were found to be reversible with either the use of standard supportive care or through dose modifications.

Because of the poor prognosis of patients with relapsed or refractory DLBCL after at least 2 previous regimens, the limitations of available therapeutic interventions, and the aging population, single-drug selinexor administered in the outpatient setting showed meaningful durable anti-DLBCL activity, the authors concluded. Responses were associated with substantially improved survival, underscoring the potential of oral XPO1 inhibition as an oral, non-chemotherapeutic option for patients with relapsed or refractory DLBCL.

In June 2020, the FDA approved selinexor for use in adult patients with relapsed/refractory DLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, following at least 2 lines of systemic therapy. The regulatory decision was based on earlier findings from SADAL, in which the drug showed an ORR of 29%, including a CR of 13%.5

Read more:
Selinexor Shows Meaningful, Durable Responses Linked With Improved OS in DLBCL - OncLive

Juno/WuXi’s cell therapy venture buys out solid tumor player in China, gaining a discovery engine and portending more M&A to come – Endpoints News

If the cell therapy field in the US is just getting started with two commercial CAR-T players, China represents an even bigger untapped market for James Li, the CEO of JW Therapeutics.

The whole space is wide open, he said.

His company, a joint venture created by Juno and WuXi AppTec, has been at the heels of its US counterparts. It has a BLA at Chinas drug regulators for the lead program targeting CD19, a revised version of Junos JCAR017; is developing a BCMA therapy to follow; and more recently got into NK cells. The team, consisting of 200-plus employees, covers everything from process development and manufacturing to regulatory affairs and quality control.

But there are some things its lacking: JW wanted to get into the solid tumor space, and it has little expertise in early-stage development, where its been relying extensively on Juno (later Celgene, now Bristol Myers Squibb).

Its now filled both those gaps by buying out Syracuse Biopharma, the Chinese subsidiary of Bay Area-based Eureka Therapeutics.

We want to build the leading T cell therapy company in China; it has to have a discovery capability, Eureka founder and president Cheng Liu told Endpoints News.

Liu noted that Eurekas connection with Juno dates back to 2016, when it licensed three Memorial Sloan Kettering-partnered binding domains to the CAR-T player to develop treatments for multiple myeloma, including one for BCMA.

Since then his staff has been solely focused on solid tumors, leveraging TCR mimic antibodies and another secretive technology that helps T cells infiltrate tumors to hone in on liver cancer. The antibodies promise to recognize targets inside tumor cells and bind to them with higher affinity than general receptors. A clinical proof-of-concept study conducted in China two years ago suggested a surprising impact; the biotech is now conducting an official Phase I/II study in liver cancer in the US.

The deal with JW which Liu views as a merger will put them on a path to file an IND in China. The construct used in the 2018 trial was two generations ago in terms of technology, Li said, so they will be taking the new candidate into trials.

Dont look for them to rush it. Having watched the drug industry evolve as Amgens founding general manager in China, Li doesnt see cell therapy getting crowded like PD-1 did, with over a dozen companies all clamoring to make the same drug. Not only do you need differentiation some biotechs are getting creative trying to stand out you also need to be consistent with creating the products.

What people dont realize is it takes a much longer time actually if you want to have a commercially viable process, to have something meaningful you can commercialize, he said.

The costs associated with building out the infrastructure means collaboration and M&A will be the way to go.

We just started a trend, he said, but I think more will be coming.

View original post here:
Juno/WuXi's cell therapy venture buys out solid tumor player in China, gaining a discovery engine and portending more M&A to come - Endpoints News

Stem Cell Alopecia Treatment Market Segmentation By Qualitative And Quantitative Research Incorporating Impact Of Economic and Non-Economic Aspects By…

New Jersey, United States,- The recent report on Stem Cell Alopecia Treatment Market offered by Verified Market Research, comprises of a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. Additionally, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the Stem Cell Alopecia Treatment market.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

In market segmentation by manufacturers, the report covers the following companies-

Exploring the growth rate over a period

Business owners looking to scale up their business can refer this report that contains data regarding the rise in sales within a given consumer base for the forecast period, 2020 to 2027. Product owners can use this information along with the driving factors such as demographics and revenue generated from other products discussed in the report to get a better analysis of their products and services. Besides, the research analysts have compared the market growth rate with product sales to enable business owners to determine the success or failure of a specific product or service.

By Type

Type 1

Type 2

By Application

Application1

Application 2

Global Stem Cell Alopecia Treatment Market Report 2020 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Stem Cell Alopecia Treatment industry.

The report at a glance

The Stem Cell Alopecia Treatment market report focuses on economic developments and consumer spending trends across different countries for the forecast period 2019 to 2026. The research further reveals which countries and regions will have a better standing in the years to come. Apart from this, the study talks about the growth rate, market share as well as the recent developments in the Stem Cell Alopecia Treatment industry worldwide. Besides, the special mention of major market players adds importance to the overall market study.

Market segment by Region/Country including:

North America (United States, Canada and Mexico) Europe (Germany, UK, France, Italy, Russia and Spain etc.) Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.) South America (Brazil, Argentina, Colombia and Chile etc.) Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)

The research provides answers to the following key questions:

What is the expected growth rate of the Stem Cell Alopecia Treatment market? What will be the market size for the forecast period, 20202027?

What are the major driving forces responsible for transforming the trajectory of the industry?

Who are major vendors dominating the Stem Cell Alopecia Treatment industry across different regions? What are their winning strategies to stay ahead in the competition?

What are the market trends business owners can rely upon in the coming years?

What are the threats and challenges expected to restrict the progress of the industry across different countries?

What are the key opportunities that business owners can bank on for the forecast period, 20202027?

Why Choose Verified Market Research?

To summarize, the global Stem Cell Alopecia Treatment market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080 UK: +44 (203)-411-9686 APAC: +91 (902)-863-5784 US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Read more here:
Stem Cell Alopecia Treatment Market Segmentation By Qualitative And Quantitative Research Incorporating Impact Of Economic and Non-Economic Aspects By...

Canine Stem Cell Therapy Expansion Projected to Gain an Uptick During 2019-2026 – Jewish Life News

Most recent report on the global Canine Stem Cell Therapy market

A recent market study reveals that the global Canine Stem Cell Therapy market is likely to grow at a CAGR of ~XX% over the forecast period (2019-2029) largely driven by factors including, factor 1, factor 2, factor 3, and factor 4. The value of the global Canine Stem Cell Therapy market is estimated to reach ~US$ XX Bn/Mn by the end of 2029 owing to consistent focus on research and development activities in the Canine Stem Cell Therapy field.

Valuable Data included in the report:

Competitive Outlook

The presented business intelligence report includes a SWOT analysis for the leading market players along with vital information including, revenue analysis, market share, pricing strategy of each market players.

Some of the top tier players profiled in the report include:

Product adoption Analysis

A complete assessment of the market share, consumption patterns, and supply-demand ratio of each product is provided backed by insightful tables, figures, and graphs. The products covered in the report include:

The resourceful market study outlines the overall prospects of the Canine Stem Cell Therapy market in the major geographies including region 1, region 2, region 3, and region 4. The most prominent market players, observable trends, opportunities, and challenges in each region is enclosed in the report.

Important Queries Addressed in the report:

Why Our Clients Trust Canine Stem Cell Therapy Market Report?

With a systematic and methodic approach, our analysts collect data from credible primary and secondary sources. In addition, we offer the most efficient after sales services to our customers and address their problems without any delay.

More here:
Canine Stem Cell Therapy Expansion Projected to Gain an Uptick During 2019-2026 - Jewish Life News

Acute Myeloid Leukemia Therapeutics Market To Reach USD 3.56 Billion By 2027 | Reports And Data – GlobeNewswire

July 22, 2020 15:04 ET | Source: Reports and Data

New York, July 22, 2020 (GLOBE NEWSWIRE) -- Market Size USD 1.46 Billion in 2019, Market Growth - CAGR of 13.1%, Market Trends Implementing various growth strategies in therapeutics.

New York, July 23, 2020-The GlobalAcute Myeloid Leukemia Therapeutics Marketis forecast to reach USD 3.56 Billion by 2027, according to a new report by Reports and Data. The global acute myeloid leukemia therapeutics market is expected to gain a lucrative increase over the forecast period due to the increasing occurrences of acute myeloid leukemia and its recurrence cases across the globe. Reinforcing the need for forwarding therapeutics is also a high-impact rendering operator of this market. Increasing occurrences of acute myeloid leukemia therapeutics are related to administrators such as genetic variations, unhealthy lifestyles, continued exposure to dangerous chemicals such as benzene, and radiation exposure. Moreover, an increase in the geriatric population base and growing unmet healthcare needs are expected to boost market growth further.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/3354

Limitations in the current drug therapies for acute myeloid leukemia could potentially give rise to the need for improved and effective treatments, also stimulating market growth. The benefits of these therapies include long-term survival rates, increased safety, and enhanced quality. Furthermore, a higher chance of early description of leukemia cells, targeted therapy, and reduced chances of relapse of the acute myeloid leukemia are further supposed to benefit the industry in the forecast period.

COVID-19 Impact:

As the COVID-19 crisis grows, producers are quickly changing their practice & purchasing priorities to meet the required demand of a pandemic. The extensive study of the segments and sub-segments looks at the overall market. Market forecasts will provide in-depth insights into industry parameters by accessing growth, consumption, upcoming market trends, and price fluctuations. The market value will affect a lot due to the higher demand for hospital visits and excessive use of medical supplies.

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/acute-myeloid-leukemia-therapeutics-market

Further key findings from the report suggest

Order Now: https://www.reportsanddata.com/checkout-form/3354

For this report, Reports and Data has segmented the Global Acute Myeloid Leukemia Therapeutics Market based on Regimen, Treatment Type, End-user, and Region:

Regimen Outlook (Revenue, USD Billion; 2017-2027)

Treatment Type Outlook (Revenue, USD Billion; 2017-2027)

End-User Outlook (Revenue, USD Billion; 2017-2027)

Regional Outlook (Revenue, USD Billion; 2017-2027)

Browse more similar reports on Therapeutics category by Reports And Data

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W Head of Business Development Reports And Data | Web: http://www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com LinkedIn | Twitter | Blogs

Read the rest here:
Acute Myeloid Leukemia Therapeutics Market To Reach USD 3.56 Billion By 2027 | Reports And Data - GlobeNewswire

Latest News On the Covid-19 impact on Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Trade Overview, Industry Demand and…

The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market.

Leading players of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market. It also provides useful recommendations for new as well as established players of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market.

Final Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Report will add the analysis of the impact of COVID-19 on this Market.

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market competition by top manufacturers/Key player Profiled: Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Fluidigm, Ikonisys, AdnaGen, IVDiagnostics, Miltenyi Biotec, ScreenCell, Silicon Biosystems

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market:

The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market was valued at $XX million in 2019, and Research analysts predict the global market size will reach $XX million by the end of 2029, growing at a CAGR of XX% between 2019 and 2029.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 210 countries and territories around the world and 2 international conveyances. The global impacts of COVID-19 are already starting to be felt, and will significantly affect this industry in 2020.

This report analyses the impact of COVID-19 on this industry. COVID-19 can affect the global market in 3 ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on enterprises and financial markets.

This report provides detailed historical analysis of global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) from 2014-2019, and provides extensive market forecasts from 2020-2029 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market.

Segmentation by Product:

CellSearch Others

Segmentation by Application:

Breast Cancer Diagnosis and Treatment Prostate Cancer Diagnosis and Treatment Colorectal Cancer Diagnosis and Treatment Lung Cancer Diagnosis and Treatment Other Cancers Diagnosis and Treatment

Competitive Analysis:

Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Scope of the Report: The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The report offers in-depth assessment of the growth and other aspects of the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market in important countries (regions), including:

North America(United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

For Customised Template PDF Report: https://www.reporthive.com/request_customization/2349943

Table of Contents

Report Overview:It includes major players of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by application, it gives a study on the consumption in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market are profiled in this section. The analysts have provided information about their recent developments in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us: Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Follow this link:
Latest News On the Covid-19 impact on Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Trade Overview, Industry Demand and...

Ascentage Pharma Announces First Patient Dosed in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 as Single Agent and in Combinations for the…

SUZHOU, China and ROCKVILLE, Md., July 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of the company's novel MDM2-p53 inhibitor candidate APG-115 as a single agent or in combinations for the treatment of Chinese patients with relapsed/refractory acute myeloid leukemia (r/r AML), or relapsed/progressed high/very high risk myelodysplastic syndrome (MDS) has dosed its first patient in China. As the first MDM2-p53 inhibitor entering clinical studies for the treatment of solid tumors in China, this is the first study of APG-115 in patients with hematologic malignancies.

This multicenter Phase Ib clinical study in China is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of APG-115 as a single agent or in combination with azacitidine or cytarabine in patients with hematologic malignancies, including r/r AML and relapsed/progressed high/very high risk MDS.

AML is a clonal proliferative disease of the bone marrow, of which the incidence rate increases with age. AML is the most common type of leukemia in China, with an incidence rate of 1.62-2.32 cases per 100,000[1]. The standard induction therapy for AML comprises the "7+3" regimen (7 days of cytarabine plus 3 days of anthracycline drugs), but up to 40% of newly diagnosed AML patients do not achieve complete response (CR) during initial induction therapy, which is considered as refractory, or relapse within 6 months after achieving CR[2].

MDS is a heterogeneous hematopoietic disease caused by abnormal pluripotent stem cells, and the condition is characterized by poor hematopoietic function, bone marrow failure, reduction in peripheral blood cells, and reduced survival rates. The incidence rate of MDS in China is approximately 5 cases per 100,000. Although hypomethylating agents can produce a high response rate in patients with MDS, many patients eventually develop drug resistance to hypomethylating agents. Patients who have developed the acquired drug resistance commonly face a very poor prognosis. In patients with high-risk MDS, treatment failure with hypomethylating agents is associated with an average survival of less than 6 months[3]. As a result, both refractory/progressed AML and MDS represent an urgent medical need for more effective therapies.

APG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2-p53 protein-protein interaction (PPI). APG-115 has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 PPI. APG-115 is the first MDM2-p53 inhibitor entering clinical development in China, with multiple ongoing clinical studies in solid tumors in China and the US. At present, APG-115 is being investigated in a range of hematologic malignancies globally.

"Currently, there remains to be significant unmet medical needs in the treatment of hematologic malignancies, including AML and MDS," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "We have also noticed that drug development targeting the MDM2-p53 pathway has received growing interest. As the first MDM2-p53 inhibitor entering clinical study in China, APG-115 has already demonstrated favorable safety profiles and preliminary efficacy in solid tumors. We will actively explore APG-115's therapeutic potential in hematologic malignancies, to hopefully provide more options of AML and MDS treatment to patients in China and around the world."

References:

1.Chang R, Wu S, Chen W, et al. Analysis on epidemiological characteristics of leukemia in Gansu Province from 2003 to 2012 [Article in Chinese]. Modern Preventive Med. 2014;41(21):3841-04.

2.Thol F, Schlenk RF, Heuser M, Ganser A. 2015. How I treat refractory and early relapsed acute myeloid leukemia. Blood 126: 319-27

3.Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, et al. 2011. Outcome of high-risk myelodysplastic syndrome after Azacitidine treatment failure. J Clin Oncol 29: 3322-7

About APG-115

APG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2-p53 PPI. APG-115 has strong binding affinity to MDM2 and is designed to activate p53 tumor suppression activity by blocking the MDM2-p53 PPI. Ascentage Pharma has previously commenced three clinical trials of APG-115 in the US, including a Phase I study as single agent, a Phase Ib/II study in combination with pembrolizumab for treatment of metastatic melanoma and other advanced solid tumors, and a Phase I/II study as a single agent or in combination with chemotherapy for treatment of salivary gland cancer. APG-115 is the first MDM2-p53 inhibitor to enter clinical studies in China. A Phase I study as a single agent, and a Phase Ib study as a single agent or in combination with chemotherapy for treatment of AML (acute myeloid leukemia) or MDS (myelodysplastic syndrome) are ongoing in China.

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and senesce diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK.

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 30 Phase I/II clinical trials in the US, Australia, and China. The company's core drug candidate HQP1351 was recently granted orphan drug and fast-track designations by the US Food and Drug Administration (FDA), and a New Drug Application for HQP1351 has been submitted in China. APG-2575, another key drug candidate of the company, was recently granted orphan drug designation by the FDA.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

SOURCE Ascentage Pharma

http://www.healthquearma.com

Read more here:
Ascentage Pharma Announces First Patient Dosed in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 as Single Agent and in Combinations for the...

Potential Combination Therapy Discovered for Treating Head and Neck Squamous Cell Carcinoma – Genetic Engineering & Biotechnology News

Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat. It is an aggressive life-threatening disease associated with high mortality rates, and accounts for more than 90% of the cancers of the head and neck.

PD1 blockade-based combination therapy has been approved as a first-line treatment for HNSCC. However, the response rate remains relatively low, and patients with HNSCC eventually relapse. Now scientists at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have revealed a potential new combination therapy to treat advanced head and neck squamous cell carcinoma. Using a mouse model, researchers found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences, and eliminated cancer stem cells.

Their findings, BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse, is published in Cell Stem Cell.

PD1 blockade combined with chemotherapy has been approved for recurrent or metastatic head and neck cancer. However, response rates remain low and response duration is suggesting that this type of cancer might be resistant to PD1 blockade.

The researchers sought to overcome the resistance and had been studying the role of cancer stem cells and the protein BMI1. BMI1, a polycomb group (PcG) protein, plays a critical role in epigenetic regulation of cell differentiation and proliferation, and cancer stem cell self-renewal.

The researchers used a mouse model of HNSCC that mimicked human cancer development and metastasis, allowing them to perform lineage tracing of BMI1-positive cancer stem cells in an undisturbed tumor immune microenvironment. Then they tested whether BMI1 cancer stem cells could be eliminated by PD1 blockade-based combination therapy using both pharmacological and genetic inhibition of BMI1.

Here, we show that the combination treatment of anti-PD1 and cisplatin enriched BMI1+ CSCs in HNSCC while inhibiting HNSCC growth. In contrast, the pharmacological and genetic inhibition of BMI1 eliminated BMI1+ CSCs and enabled PD1 blockade therapy, resulting in the inhibition of metastatic HNSCC and prevention of HNSCC relapses, the researchers wrote.

BMI1 inhibition induced tumor cell-intrinsic immune responses by recruiting and activating CD8+ T cells along with eliminating BMI1 and cancer stem cells.

This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminates cancer stem cells by activating antitumor immunity. This discovery holds promise for those with advanced head and neck cancers who are treated with PD1 blockade, but later become resistant to therapy.

See the article here:
Potential Combination Therapy Discovered for Treating Head and Neck Squamous Cell Carcinoma - Genetic Engineering & Biotechnology News